(Q35057227)

6 August 2017

1 reference

title

The diagnosis of primary progressive multiple sclerosis (English)

1 reference

primary progressive multiple sclerosis

6 August 2017

main subject

0 references

author name string

Jerry S Wolinsky

series ordinal

1

1 reference

6 August 2017

PROMiSe Study Group

series ordinal

2

1 reference

6 August 2017

publication date

1 February 2003

1 reference

Journal of the Neurological Sciences

6 August 2017

published in

1 reference

6 August 2017

volume

206

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

145-152

1 reference

Multiple sclerosis: a review.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Defining the clinical course of multiple sclerosis: Results of an international survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Primary and transitional progressive MS: a clinical and MRI cross-sectional study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

A comparison of the pathology of primary and secondary progressive multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Primary progressive multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Application of the Poser criteria in primary progressive multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Clinical and laboratory features of primary progressive and secondary progressive MS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

A preliminary study comparing the sensitivity of serial monthly enhanced MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in primary progressive multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

Clinical definition for multiple sclerosis treatment trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

CSF oligoclonal bands, MRI, and the diagnosis of multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900346-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-510X(02)00346-5

1 reference

6 August 2017

1 reference